Edit

Tobacco Regulation Report

The latest national tobacco rules and news—and what may be on the horizon
Tobacco Regulation Report

Action Plan: Moving on Flavors

On the issue of flavors, including flavored e-cigarettes and e-liquids, the FDA said it is concerned about youth and their exposure to nicotine but also understands the role flavored tobacco products ...

Tobacco Regulation Report

Action Plan: Next Steps

While the FDA has taken several high-profile actions regarding e-cigarettes and its own application-review process in recent months, the path to developing standards and regulations has several steps ...

The FDA wants to explore opportunities for premarket review efficiencies in the hopes it can “modernize and improve the review process.” The FDA hopes to inject an increased flexibility an...

The FDA has begun exploring a product standard for e-cigarettes. As part of that standard-development process, the agency will consider, among other things, levels of toxicants and impurities in propy...

About a year after announcing a tobacco strategy involving nicotine levels in cigarettes and other related measures to reduce tobacco use among Americans, the U.S. Food and Drug Administration (FDA) s...

The FDA also wants to find ways to more efficiently become aware of violations affecting youth use of e-cigarettes, such as illegal product marketing to youth. The agency seeks to be faster and more a...

The FDA will hold a public meeting on the premarket application and review process Oct. 22-23. The goal of the meeting is to solicit comments on its processes and provide a dedicated venue for specifi...

The U.S. Food and Drug Administration (FDA) continues its review of tobacco products to determine if manufacturers can claim them to be modified-risk or reduced-risk as compared to traditional combust...

By law, the FDA must refer MRTP applications to TPSAC, and TPSAC must report its recommendations on the applications. The FDA reviews and makes the determination as to whether to authorize an MRTP, an...

In a public hearing conducted Jan. 24-25, TPSAC voted on several scientific recommendations for the FDA to consider in the agency’s ongoing review of New York-based Philip Morris International&r...

  • Page 3